Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Monday 30 September, 2019

Evgen Pharma PLC

ESMO presentation of Phase II STEM clinical data

RNS Number : 0326O
Evgen Pharma PLC
30 September 2019

Evgen Pharma plc

 ("Evgen" or the "Company")


ESMO presentation of Phase II STEM clinical data


Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that the clinical data from the completed open-label Phase II STEM trial was presented in poster format yesterday at the 2019 European Society of Medical Oncology Congress ("ESMO") in Barcelona. ESMO is the most influential oncology meeting in Europe and is held in partnership with the European Association for Cancer Research (EACR).


The poster, titled "STEM: SFX-01 in the Treatment and Evaluation of Metastatic breast cancer" can now be viewed here:


The trial investigated the potential of SFX-01 to reverse acquired resistance to endocrine therapies such as tamoxifen, fulvestrant and third generation aromatase inhibitors. The trial met the primary endpoints with data demonstrating that SFX-01 is well tolerated with no safety concerns in patients suffering from ER+ metastatic (Stage 4) breast cancer. The trial data also showed that SFX-01, in combination with endocrine therapy, demonstrated both anti-tumour activity and prolonged disease stabilisation in heavily pre-treated patients progressing on endocrine therapy at entry to the study.


Steve Franklin, CEO of Evgen Pharma, said: ''Metastatic breast cancer is incurable, so all therapies for this indication have the aim of improving the quality of life these patients have, for the time they have left. SFX-01 has been shown not only to halt the growth of a tumour that is progressing, and in some cases to significantly shrink the tumour, but to do this with very few side effects - something rarely seen in the field of oncology. This makes us very excited for the future of SFX-01 in breast cancer, particularly when targeting earlier stages of the disease where one would expect SFX-01 to have even greater impact on halting or reversing tumour growth.''




Evgen Pharma plc 

via Walbrook 

Dr Stephen Franklin, CEO 


Richard Moulson, CFO 





+44 (0) 20 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance) 


Alice Lane, Manasa Patil (ECM) 




WG Partners LLP 

+44 (0) 20 3705 9330 

Nigel Barnes / Claes Spång  




Walbrook PR 

+44 (0)20 7933 87870 or [email protected]

Paul McManus / Anna Dunphy 

+44 (0)7980 541 893 / +44 (0)7876 741 001 



About Evgen Pharma plc 


Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.  


The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 


For further information, please visit: 



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t